{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:21Z","timestamp":1790959341480,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Finasteride, a 5\u03b1-reductase inhibitor used in benign prostatic hyperplasia and androgenetic alopecia, has been associated with an increased suicidal risk, whereas it is unclear whether such risk is similar to that for another 5\u03b1-reductase inhibitor, dutasteride. We aimed to assess the risk of suicidal behaviours with finasteride relative to dutasteride. A nationwide cohort study was conducted using the French National Health Data System (SNDS). Men aged 50\u00a0years or older initiating finasteride 5\u00a0mg or dutasteride 0.5\u00a0mg in France between 01-01-2012 and 30-06-2016 were included and followed until outcome (suicide death identified from death certificate or self-harm hospitalisation), treatment discontinuation or switch, death, or 31-12-2016. Self-harm by violent means or resulting in admission to an intensive care unit were also examined. Cox proportional hazards models controlled for age and psychiatric and non-psychiatric conditions by inverse probability of treatment weighting (IPTW). Analyses were stratified according to psychiatric history. The study compared 69,786 finasteride new users to 217,577 dutasteride new users (median age: 72.0\u00a0years [Q1\u2013Q3\u2009=\u200964.5\u201380.2] vs. 71.1 [Q1\u2013Q3\u2009=\u200965.0\u201379.2]). During follow-up, 18 suicide deaths (0.57\/1000 person-years) and 34 self-harm hospitalisations (1.08\/1000) occurred among finasteride users versus 47 deaths (0.43\/1000) and 87 hospitalisations (0.79\/1000) among dutasteride users. Overall, finasteride was not associated with an increased risk of any suicidal outcome (IPTW-adjusted Hazard Ratio\u2009=\u20091.21 [95% Confidence Interval\u2009 .87\u20131.67]), suicide death or self-harm hospitalisation. However, among individuals with a history of mood disorders, finasteride was associated with an increased risk of any suicidal outcome (25 versus 46 events; HR\u2009=\u20091.64 [95% CI 1.00\u20132.68]), suicide death (8 versus 10 events; HR\u2009=\u20092.71 [95% CI 1.07\u20136.91]), self-harm by violent means (6 versus 6 events; HR\u2009=\u20093.11 [95% CI 1.01\u20139.61]), and self-harm with admission to an intensive care unit (7 versus 5 events; HR\u2009=\u20093.97 [95% CI 1.26\u201312.5]). None of these risks was significantly increased among individuals without a psychiatric history. These findings do not support an increased risk of suicide with finasteride used in the treatment of benign prostatic hyperplasia. However, an increased risk cannot be excluded among men with a history of mood disorder, but this result based on a limited number of events should be interpreted with caution.<\/jats:p>","DOI":"10.1038\/s41598-023-32356-3","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:03:03Z","timestamp":1680256983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Moussa","family":"Laanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jollant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"32356_CR1","unstructured":"Levine, D. & Terhune, C. Exclusive: Merck anti-baldness drug Propecia has long trail of suicide reports, records show [Internet]. Reuters. 2021. Available from: https:\/\/www.reuters.com\/article\/us-merck-propecia-suicide-exclusive-idUSKBN2A32XU"},{"issue":"9","key":"32356_CR2","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4088\/JCP.12m07887","volume":"73","author":"MS Irwig","year":"2012","unstructured":"Irwig, M. S. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J. Clin. Psychiatry. 73(9), 1220\u20131223 (2012).","journal-title":"J. Clin. Psychiatry."},{"issue":"3","key":"32356_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1557988314538445","volume":"9","author":"CA Ganzer","year":"2015","unstructured":"Ganzer, C. A., Jacobs, A. R. & Iqbal, F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am. J. Mens Health. 9(3), 222\u2013228 (2015).","journal-title":"Am. J. Mens Health."},{"issue":"7","key":"32356_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/phar.1612","volume":"35","author":"AK Ali","year":"2015","unstructured":"Ali, A. K., Heran, B. S. & Etminan, M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study. Pharmacotherapy 35(7), 687\u2013695 (2015).","journal-title":"Pharmacotherapy"},{"key":"32356_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2018.06.022","volume":"120","author":"WR Baas","year":"2018","unstructured":"Baas, W. R. et al. A review of the FAERS data on 5-alpha reductase inhibitors: implications for postfinasteride syndrome. Urology 120, 143\u2013149 (2018).","journal-title":"Urology"},{"issue":"5","key":"32356_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","volume":"177","author":"B Welk","year":"2017","unstructured":"Welk, B. et al. Association of suicidality and depression with 5\u03b1-reductase inhibitors. JAMA Intern. Med. 177(5), 683\u201391 (2017).","journal-title":"JAMA Intern. Med."},{"key":"32356_CR7","first-page":"1","volume":"14","author":"MS Irwig","year":"2020","unstructured":"Irwig, M. S. Finasteride and suicide: a postmarketing case series. Dermatol. Basel Switz. 14, 1\u20136 (2020).","journal-title":"Dermatol. Basel Switz."},{"issue":"3","key":"32356_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/JCP.0000000000001379","volume":"41","author":"M Pompili","year":"2021","unstructured":"Pompili, M. et al. Risk of depression associated with finasteride treatment. J. Clin. Psychopharmacol. 41(3), 304\u2013309 (2021).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"32356_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/PSY.0000000000000784","volume":"82","author":"JA Kim","year":"2020","unstructured":"Kim, J. A., Choi, D., Choi, S., Chang, J. & Park, S. M. The association of 5\u03b1-reductase inhibitor with suicidality. Psychosom. Med. 82(3), 331\u2013336 (2020).","journal-title":"Psychosom. Med."},{"issue":"9","key":"32356_CR10","first-page":"1251","volume":"155","author":"JC Nickel","year":"1996","unstructured":"Nickel, J. C. et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian 2 year Study. CMAJ Can. Med. Assoc. J. J. Assoc. Med. Can. 155(9), 1251\u20139 (1996).","journal-title":"CMAJ Can. Med. Assoc. J. J. Assoc. Med. Can."},{"issue":"2","key":"32356_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0149-2918(97)80113-0","volume":"19","author":"JL Tenover","year":"1997","unstructured":"Tenover, J. L., Pagano, G. A., Morton, A. S., Liss, C. L. & Byrnes, C. A. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. Clin Ther. 19(2), 243\u201358 (1997).","journal-title":"Clin Ther."},{"issue":"3","key":"32356_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","volume":"61","author":"H Wessells","year":"2003","unstructured":"Wessells, H. et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 61(3), 579\u2013584 (2003).","journal-title":"Urology"},{"issue":"10","key":"32356_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1346-8138.2002.tb00200.x","volume":"29","author":"G Altomare","year":"2002","unstructured":"Altomare, G. & Capella, G. L. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J. Dermatol. 29(10), 665\u2013669 (2002).","journal-title":"J. Dermatol."},{"issue":"6","key":"32356_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6904-6-7","volume":"7","author":"B Rahimi-Ardabili","year":"2006","unstructured":"Rahimi-Ardabili, B., Pourandarjani, R., Habibollahi, P. & Mualeki, A. Finasteride induced depression: a prospective study. BMC Clin. Pharmacol. 7(6), 7 (2006).","journal-title":"BMC Clin. Pharmacol."},{"issue":"3","key":"32356_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","volume":"8","author":"AM Traish","year":"2011","unstructured":"Traish, A. M., Hassani, J., Guay, A. T., Zitzmann, M. & Hansen, M. L. Adverse side effects of 5\u03b1-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J. Sex. Med. 8(3), 872\u2013884 (2011).","journal-title":"J. Sex. Med."},{"issue":"10","key":"32356_CR16","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1111\/jsm.12269","volume":"10","author":"RC Melcangi","year":"2013","unstructured":"Melcangi, R. C. et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious\/depressive symptomatology. J. Sex. Med. 10(10), 2598\u20132603 (2013).","journal-title":"J. Sex. Med."},{"key":"32356_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jsbmb.2014.03.012","volume":"146","author":"D Caruso","year":"2015","unstructured":"Caruso, D. et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J. Steroid Biochem. Mol. Biol. 146, 74\u201379 (2015).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"32356_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1055\/s-0030-1249095","volume":"43","author":"B R\u00f6mer","year":"2010","unstructured":"R\u00f6mer, B. et al. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry 43(5), 174\u2013178 (2010).","journal-title":"Pharmacopsychiatry"},{"issue":"366","key":"32356_CR19","doi-asserted-by":"publisher","first-page":"l5047","DOI":"10.1136\/bmj.l5047","volume":"9","author":"SL Gray","year":"2019","unstructured":"Gray, S. L. & Semla, T. P. Post-finasteride syndrome. BMJ 9(366), l5047 (2019).","journal-title":"BMJ"},{"issue":"1","key":"32356_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1557988316631624","volume":"12","author":"CA Ganzer","year":"2018","unstructured":"Ganzer, C. A. & Jacobs, A. R. Emotional consequences of finasteride: fool\u2019s gold. Am. J. Mens Health. 12(1), 90\u201395 (2018).","journal-title":"Am. J. Mens Health."},{"issue":"12","key":"32356_CR21","doi-asserted-by":"publisher","first-page":"djw168","DOI":"10.1093\/jnci\/djw168","volume":"108","author":"JM Unger","year":"2016","unstructured":"Unger, J. M. et al. Long-term consequences of finasteride versus placebo in the prostate cancer prevention trial. J. Natl. Cancer Inst. 108(12), djw168. https:\/\/doi.org\/10.1093\/jnci\/djw168 (2016).","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"32356_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/phar.1925","volume":"37","author":"KW Hagberg","year":"2017","unstructured":"Hagberg, K. W., Divan, H. A., Nickel, J. C. & Jick, S. S. Risk of incident antidepressant-treated depression associated with use of 5\u03b1-reductase inhibitors compared with use of \u03b1-blockers in men with benign prostatic hyperplasia: a population-based study using the clinical practice research datalink. Pharmacotherapy 37(5), 517\u2013527 (2017).","journal-title":"Pharmacotherapy"},{"issue":"1","key":"32356_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/pds.671","volume":"11","author":"GM Clifford","year":"2002","unstructured":"Clifford, G. M. & Farmer, R. D. T. Drug or symptom-induced depression in men treated with alpha 1-blockers for benign prostatic hyperplasia? A nested case-control study. Pharmacoepidemiol. Drug Saf. 11(1), 55\u201361 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"32356_CR24","doi-asserted-by":"publisher","first-page":"JC9","DOI":"10.7326\/ACPJC-2017-167-2-009","volume":"167","author":"CC Dacso","year":"2017","unstructured":"Dacso, C. C. In older men, 5\u03b1-reductase inhibitors were linked to increased risk for self-harm and depression but not suicide. Ann. Intern. Med. 167(2), JC9. https:\/\/doi.org\/10.7326\/ACPJC-2017-167-2-009 (2017).","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"32356_CR25","first-page":"956","volume":"198","author":"SA Kaplan","year":"2017","unstructured":"Kaplan, S. A. Re: association of suicidality and depression with 5\u03b1-reductase inhibitors. J. Urol. 198(5), 956\u2013957 (2017).","journal-title":"J. Urol."},{"issue":"5","key":"32356_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamainternmed.2017.0096","volume":"177","author":"S Thielke","year":"2017","unstructured":"Thielke, S. The risk of suicidality and depression from 5-\u03b1 reductase inhibitors. JAMA Intern. Med. 177(5), 691\u2013692 (2017).","journal-title":"JAMA Intern. Med."},{"issue":"16","key":"32356_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.purol.2012.10.001","volume":"22","author":"A Descazeaud","year":"2012","unstructured":"Descazeaud, A. et al. Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association. Progres En. Urol. J. Assoc. Francaise Urol. Soc. Francaise Urol. 22(16), 977\u2013988 (2012).","journal-title":"Progres En. Urol. J. Assoc. Francaise Urol. Soc. Francaise Urol."},{"key":"32356_CR28","first-page":"1265","volume-title":"Foye\u2019s Principles of Medicinal Chemistry","author":"DD Miller","year":"2008","unstructured":"Miller, D. D., Brueggemeier, R. W. & Dalton, J. T. Men\u2019s health. In Foye\u2019s Principles of Medicinal Chemistry (eds Foye, W. O. et al.) 1265\u2013300 (Lippincott Williams & Wilkins, 2008)."},{"issue":"3","key":"32356_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","volume":"108","author":"JC Nickel","year":"2011","unstructured":"Nickel, J. C. et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 108(3), 388\u2013394 (2011).","journal-title":"BJU Int."},{"issue":"1","key":"32356_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","volume":"157","author":"DD Nguyen","year":"2021","unstructured":"Nguyen, D. D. et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 157(1), 35\u201342 (2021).","journal-title":"JAMA Dermatol."},{"issue":"9","key":"32356_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/1346-8138.13310","volume":"43","author":"Y Tsunemi","year":"2016","unstructured":"Tsunemi, Y. et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J. Dermatol. 43(9), 1051\u20131058 (2016).","journal-title":"J. Dermatol."},{"issue":"296","key":"32356_CR32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jad.2021.09.045","volume":"1","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Depressive symptoms in individuals diagnosed with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH) in middle-aged and older Chinese individuals: results from the china health and retirement longitudinal study. J. Affect. Disord. 1(296), 660\u2013666 (2022).","journal-title":"J. Affect. Disord."},{"issue":"3","key":"32356_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.5407","volume":"31","author":"R Sendor","year":"2022","unstructured":"Sendor, R. & St\u00fcrmer, T. Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators. Pharmacoepidemiol. Drug Saf. 31(3), 261\u2013269 (2022).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"11","key":"32356_CR34","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","volume":"149","author":"M Salas","year":"1999","unstructured":"Salas, M., Hotman, A. & Stricker, B. H. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am. J. Epidemiol. 149(11), 981\u2013983 (1999).","journal-title":"Am. J. Epidemiol."},{"issue":"Suppl 4","key":"32356_CR35","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin, P. et al. Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev. Epidemiol. Sante Publique. 65(Suppl 4), S149\u2013S167 (2017).","journal-title":"Rev. Epidemiol. Sante Publique."},{"key":"32356_CR36","unstructured":"Classification commune des actes m\u00e9dicaux. Bull. Off. (2007\/3 bis) (2007)."},{"issue":"10","key":"32356_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.revmed.2016.01.011","volume":"37","author":"G Rey","year":"2016","unstructured":"Rey, G. Death certificate data in France: production process and main types of analyses. Rev. Med. Int. 37(10), 685\u2013693 (2016).","journal-title":"Rev. Med. Int."},{"key":"32356_CR38","unstructured":"ICD-10: International Statistical Classification of Diseases and Health-Related Problems. Vol. 2. WHO; (1992)."},{"issue":"358","key":"32356_CR39","doi-asserted-by":"publisher","first-page":"j3776","DOI":"10.1136\/bmj.j3776","volume":"7","author":"S Tubiana","year":"2017","unstructured":"Tubiana, S. et al. Dental procedures, antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: nationwide population based cohort and a case crossover study. BMJ 7(358), j3776 (2017).","journal-title":"BMJ"},{"issue":"17","key":"32356_CR40","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre, M. et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 318(17), 1679\u20131686 (2017).","journal-title":"JAMA"},{"issue":"7","key":"32356_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40263-018-0537-1","volume":"32","author":"S Billioti de Gage","year":"2018","unstructured":"Billioti de Gage, S. et al. Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the french national health insurance database. CNS Drugs 32(7), 673\u201384 (2018).","journal-title":"CNS Drugs"},{"issue":"2","key":"32356_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M18-1512","volume":"170","author":"A Meyer","year":"2019","unstructured":"Meyer, A. et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study. Ann. Intern. Med. 170(2), 99 (2019).","journal-title":"Ann. Intern. Med."},{"issue":"20","key":"32356_CR43","doi-asserted-by":"publisher","first-page":"e2168","DOI":"10.1212\/WNL.0000000000009180","volume":"94","author":"C Grave","year":"2020","unstructured":"Grave, C. et al. Seasonal influenza vaccine and Guillain-Barr\u00e9 syndrome: a self-controlled case series study. Neurology 94(20), e2168\u2013e2179 (2020).","journal-title":"Neurology"},{"key":"32356_CR44","doi-asserted-by":"publisher","first-page":"n37","DOI":"10.1136\/bmj.n37","volume":"3","author":"A Weill","year":"2021","unstructured":"Weill, A. et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ 3, n37 (2021).","journal-title":"BMJ"},{"issue":"67","key":"32356_CR45","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.respe.2019.01.084","volume":"1","author":"A Tanguy-Melac","year":"2019","unstructured":"Tanguy-Melac, A. et al. Causes de d\u00e9c\u00e8s en 2015 des personnes du r\u00e9gime g\u00e9n\u00e9ral prises en en charge pour cancer en 2014\u20132015 selon leur lieu de d\u00e9c\u00e8s: utilisation du Syst\u00e8me national des donn\u00e9es de sant\u00e9. Rev. D\u00c9pid\u00e9miol. Sant\u00e9 Publique. 1(67), S102 (2019).","journal-title":"Rev. D\u00c9pid\u00e9miol. Sant\u00e9 Publique."},{"issue":"5","key":"32356_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"issue":"2","key":"32356_CR47","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","volume":"54","author":"A Bannay","year":"2016","unstructured":"Bannay, A. et al. The best use of the charlson comorbidity index with electronic health care database to predict mortality. Med. Care. 54(2), 188\u2013194 (2016).","journal-title":"Med. Care."},{"key":"32356_CR48","volume-title":"Causal Inference: What If","author":"MA Hern\u00e1n","year":"2020","unstructured":"Hern\u00e1n, M. A. & Robins, J. M. Causal Inference: What If (Chapman & Hall\/CRC, 2020)."},{"issue":"3","key":"32356_CR49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra1902944","volume":"382","author":"S Fazel","year":"2020","unstructured":"Fazel, S. & Runeson, B. Suicide. N. Engl. J. Med. 382(3), 266\u2013274 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"32356_CR50","first-page":"153","volume":"13","author":"E Chesney","year":"2014","unstructured":"Chesney, E., Goodwin, G. M. & Fazel, S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry Off. J. World Psychiatr. Assoc. WPA. 13(2), 153\u2013160 (2014).","journal-title":"World Psychiatry Off. J. World Psychiatr. Assoc. WPA."},{"key":"32356_CR51","unstructured":"R Core Team. In: R: A Language and Environment for Statistical Computing. (The R Foundation for Statistical Computing, 2019). Available from: https:\/\/www.R-project.org\/."},{"issue":"3","key":"32356_CR52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1046\/j.1365-2133.1999.03030.x","volume":"141","author":"TF Cash","year":"1999","unstructured":"Cash, T. F. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br. J. Dermatol. 141(3), 398\u2013405 (1999).","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"32356_CR53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-3083.2001.00229.x","volume":"15","author":"D Williamson","year":"2001","unstructured":"Williamson, D., Gonzalez, M. & Finlay, A. The effect of hair loss on quality of life. J. Eur. Acad. Dermatol. Venereol. 15(2), 137\u2013139 (2001).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"32356_CR54","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/j.1742-1241.2012.03010.x","volume":"66","author":"SA Kaplan","year":"2012","unstructured":"Kaplan, S. A., Chung, D. E., Lee, R. K., Scofield, S. & Te, A. E. A 5-year retrospective analysis of 5\u03b1-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int. J. Clin. Pract. 66(11), 1052\u20131055 (2012).","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"32356_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/JCP.0000000000001485","volume":"41","author":"RJ Baldessarini","year":"2021","unstructured":"Baldessarini, R. J. & Pompili, M. Further studies of effects of finasteride on mood and suicidal risk. J. Clin. Psychopharmacol. 41(6), 687\u2013688 (2021).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"32356_CR56","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1038\/s41591-022-02046-0","volume":"28","author":"P Surendran","year":"2022","unstructured":"Surendran, P. et al. Rare and common genetic determinants of metabolic individuality and their effects on human health. Nat. Med. 28(11), 2321\u20132332 (2022).","journal-title":"Nat. Med."},{"issue":"191","key":"32356_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.physbeh.2018.03.036","volume":"01","author":"C Maurice-G\u00e9linas","year":"2018","unstructured":"Maurice-G\u00e9linas, C., Deslauriers, J., Monpays, C., Sarret, P. & Grignon, S. The 5\u03b1-reductase inhibitor finasteride increases suicide-related aggressive behaviors and blocks clozapine-induced beneficial effects in an animal model of schizophrenia. Physiol. Behav. 01(191), 65\u201372 (2018).","journal-title":"Physiol. Behav."},{"key":"32356_CR58","doi-asserted-by":"publisher","first-page":"112100","DOI":"10.1016\/j.biopha.2021.112100","volume":"143","author":"T Saengmearnuparp","year":"2021","unstructured":"Saengmearnuparp, T., Lojanapiwat, B., Chattipakorn, N. & Chattipakorn, S. The connection of 5-alpha reductase inhibitors to the development of depression. Biomed. Pharmacother. 143, 112100 (2021).","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"32356_CR59","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/npp.2015.246","volume":"41","author":"PE Martinez","year":"2016","unstructured":"Martinez, P. E. et al. 5\u03b1-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology 41(4), 1093\u20131102 (2016).","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"32356_CR60","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1473-2165.2010.00533.x","volume":"9","author":"B R\u00f6mer","year":"2010","unstructured":"R\u00f6mer, B. & Gass, P. Finasteride-induced depression: new insights into possible pathomechanisms. J. Cosmet. Dermatol. 9(4), 331\u2013332 (2010).","journal-title":"J. Cosmet. Dermatol."},{"issue":"99","key":"32356_CR61","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.psyneuen.2018.09.021","volume":"1","author":"S Diviccaro","year":"2019","unstructured":"Diviccaro, S. et al. Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. Psychoneuroendocrinology 1(99), 206\u2013215 (2019).","journal-title":"Psychoneuroendocrinology"},{"issue":"365","key":"32356_CR62","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbr.2019.03.006","volume":"03","author":"RB Sasibhushana","year":"2019","unstructured":"Sasibhushana, R. B., Shankaranarayana Rao, B. S. & Srikumar, B. N. Repeated finasteride administration induces depression-like behavior in adult male rats. Behav. Brain Res. 03(365), 185\u2013189 (2019).","journal-title":"Behav. Brain Res."},{"issue":"6","key":"32356_CR63","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.juro.2013.12.014","volume":"191","author":"CW Fwu","year":"2014","unstructured":"Fwu, C. W. et al. Change in sexual function in men with lower urinary tract symptoms\/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J. Urol. 191(6), 1828\u20131834 (2014).","journal-title":"J. Urol."},{"issue":"6","key":"32356_CR64","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","volume":"4","author":"N Mondaini","year":"2007","unstructured":"Mondaini, N. et al. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon?. J. Sex. Med. 4(6), 1708\u20131712 (2007).","journal-title":"J. Sex. Med."},{"issue":"10","key":"32356_CR65","doi-asserted-by":"publisher","first-page":"e0203479","DOI":"10.1371\/journal.pone.0203479","volume":"13","author":"JH Kim","year":"2018","unstructured":"Kim, J. H. et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis. PLoS One 13(10), e0203479 (2018).","journal-title":"PLoS One"},{"issue":"3","key":"32356_CR66","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1046\/j.1464-410X.1996.00091.x","volume":"78","author":"L Wilton","year":"1996","unstructured":"Wilton, L. et al. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br. J. Urol. 78(3), 379\u2013384 (1996).","journal-title":"Br. J. Urol."},{"key":"32356_CR67","doi-asserted-by":"publisher","first-page":"e3020","DOI":"10.7717\/peerj.3020","volume":"5","author":"T Kiguradze","year":"2017","unstructured":"Kiguradze, T. et al. Persistent erectile dysfunction in men exposed to the 5\u03b1-reductase inhibitors, finasteride, or dutasteride. PeerJ 5, e3020 (2017).","journal-title":"PeerJ"},{"issue":"9","key":"32356_CR68","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4111\/kju.2011.52.9.632","volume":"52","author":"BH Chi","year":"2011","unstructured":"Chi, B. H. & Kim, S. C. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J. Urol. 52(9), 632\u2013636 (2011).","journal-title":"Korean J. Urol."},{"key":"32356_CR69","unstructured":"Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key. Prescrire Int. 25(175):242. (2016)."},{"key":"32356_CR70","doi-asserted-by":"crossref","unstructured":"Ambar Akkaoui, M., Chan-Chee, C., Laaidi, K., Fifre, G., Lejoyeux, M. & Vaiva, G. et al. In: Seasonal Changes and Decrease of Suicides and Suicide Attempts in France Over the Last 10 Years. In Review; 2021 Nov. Available from: https:\/\/www.researchsquare.com\/article\/rs-1031840\/v1.","DOI":"10.21203\/rs.3.rs-1031840\/v1"},{"issue":"12","key":"32356_CR71","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nrn3839","volume":"15","author":"G Turecki","year":"2014","unstructured":"Turecki, G. The molecular bases of the suicidal brain. Nat. Rev. Neurosci. 15(12), 802\u2013816 (2014).","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"32356_CR72","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/0006-3223(92)90084-D","volume":"32","author":"A Roy","year":"1992","unstructured":"Roy, A. Hypothalamic-pituitary-adrenal axis function and suicidal behavior in depression. Biol. Psychiatry 32(9), 812\u2013816 (1992).","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"32356_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.3334","volume":"22","author":"ES Johnson","year":"2013","unstructured":"Johnson, E. S. et al. The incident user design in comparative effectiveness research: user design in comparative effectiveness. Pharmacoepidemiol. Drug Saf. 22(1), 1\u20136 (2013).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"32356_CR74","first-page":"201","volume":"2","author":"C Quantin","year":"2016","unstructured":"Quantin, C. et al. \u00c9tude des algorithmes de rep\u00e9rage de la d\u00e9pression dans le SNIIRAM par le r\u00e9seau REDSIAM. Rev. Fr. Aff. Soc. 2(6), 201\u2013225 (2016).","journal-title":"Rev. Fr. Aff. Soc."},{"issue":"9","key":"32356_CR75","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","volume":"60","author":"A Rachas","year":"2022","unstructured":"Rachas, A. et al. The economic burden of disease in France from the national health insurance perspective: the healthcare expenditures and conditions mapping used to prepare the french social security funding act and the public health act. Med. Care. 60(9), 655\u2013664 (2022).","journal-title":"Med. Care."},{"issue":"4","key":"32356_CR76","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4103\/ijt.ijt_6_19","volume":"11","author":"S Gupta","year":"2019","unstructured":"Gupta, S., Goyal, I. & Mahendra, A. Quality of life assessment in patients with androgenetic alopecia. Int. J. Trichol. 11(4), 147 (2019).","journal-title":"Int. J. Trichol."},{"issue":"6","key":"32356_CR77","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/0190-9622(92)70134-2","volume":"26","author":"TF Cash","year":"1992","unstructured":"Cash, T. F. The psychological effects of androgenetic alopecia in men. J. Am. Acad. Dermatol. 26(6), 926\u2013931 (1992).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"32356_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.respe.2010.01.001","volume":"58","author":"C Cohidon","year":"2010","unstructured":"Cohidon, C., Santin, G., Geoffroy-Perez, B. & Imbernon, E. Suicide and occupation in France. Rev. D\u00e9pid\u00e9miol. Sant\u00e9 Publique. 58(2), 139\u2013150 (2010).","journal-title":"Rev. D\u00e9pid\u00e9miol. Sant\u00e9 Publique."},{"issue":"4","key":"32356_CR79","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/1059924X.2016.1211052","volume":"21","author":"C Bossard","year":"2016","unstructured":"Bossard, C., Santin, G. & Guseva, C. I. Suicide among farmers in France: occupational factors and recent trends. J. Agromed. 21(4), 310\u2013315 (2016).","journal-title":"J. Agromed."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32356-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32356-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32356-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:05:22Z","timestamp":1680260722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32356-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32356"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32356-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5308"}}